Sitagliptin Augments Sympathetic Enhancement of the Renovascular Effects of Angiotensin II in Genetic Hypertension
- 1 June 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 51 (6) , 1637-1642
Abstract
Dipeptidyl peptidase IV converts neuropeptide Y1-36(Y1-receptor agonist released from renal sympathetic nerves) to neuropeptide Y3-36(selective Y2-receptor agonist). Previous studies suggest that Y1, but not Y2, receptors enhance renovascular responses to angiotensin II in kidneys from genetically-susceptible animals. Therefore, we hypothesized that inhibition of dipeptidyl peptidase IV with sitagliptin (antidiabetic drug) would augment the ability of exogenous and endogenous neuropeptide Y1-36to enhance renal vascular responses to angiotensin II in kidneys from spontaneously hypertensive rats. This hypothesis was tested using 3 protocols in isolated perfused kidneys. Results from Protocol 1: Exogenous neuropeptide Y1-36enhanced renovascular responses to angiotensin II. This effect of neuropeptide Y1-36was blocked by BIBP3226 (selective Y1receptor antagonist); Exogenous neuropeptide Y3-36did not enhance renovascular responses to angiotensin II. Results from Protocol 2: Sitagliptin augmented the ability of exogenous neuropeptide Y1-36to enhance renovascular responses to angiotensin II. This effect of sitagliptin was blocked by BIBP3226. Results from Protocol 3: Renal sympathetic nerve stimulation enhanced renovascular responses to angiotensin II; this enhancement was augmented by sitagliptin and abolished by BIBP3226. Neuropeptide Y1-36via Y1receptors enhances renovascular responses to angiotensin II in kidneys from genetically hypertensive animals. Sitagliptin, by blocking dipeptidyl peptidase IV, prevents metabolism of neuropeptide Y1-36and thereby increases the effects of neuropeptide Y1-36released from renal sympathetic nerves on Y1receptors leading to augmentation of neuropeptide Y1-36–induced enhancement of the renovascular effects of angiotensin II. The renal effects of dipeptidyl peptidase IV inhibitors in hypertensive diabetic patients merit a closer examination.Keywords
This publication has 19 references indexed in Scilit:
- Dipeptidyl peptidase IV inhibition downregulates Na+-H+exchanger NHE3 in rat renal proximal tubuleAmerican Journal of Physiology-Renal Physiology, 2008
- Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated AngioedemaHypertension, 2008
- Inhibition of Renal Dipeptidyl Peptidase IV Enhances Peptide YY1–36-Induced Potentiation of Angiotensin II-Mediated Renal Vasoconstriction in Spontaneously Hypertensive RatsThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Role of Renal Sympathetic Nerves in Regulating Renovascular Responses to Angiotensin II in Spontaneously Hypertensive RatsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Pancreatic Polypeptide-Fold Peptide Receptors and Angiotensin II–Induced Renal VasoconstrictionHypertension, 2006
- Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?Regulatory Peptides, 2005
- Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cellsAmerican Journal of Physiology-Cell Physiology, 2004
- α2-Adrenoceptors Potentiate Angiotensin II- and Vasopressin-Induced Renal Vasoconstriction in Spontaneously Hypertensive RatsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Association of Na+-H+ Exchanger Isoform NHE3 and Dipeptidyl Peptidase IV in the Renal Proximal TubuleJournal of Biological Chemistry, 2001
- Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gutPflügers Archiv - European Journal of Physiology, 1997